Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice

Schatteman, Gina C.; Hanlon, Heather D.; Jiao, Chunhua; Dodds, Sherry G.; Christy, Barbara A.

doi:10.1172/jci9087

Cited by 454 publications

(390 citation statements)

References 26 publications

Supporting

Mentioning

359

Contrasting

Unclassified

Order By: Relevance

“…14 The angiogenic growth factor VEGF, which is upregulated in the ischemic myocardium of patients with myocardial infarction, 22 has been shown to mobilize EPCs in both mice and men. 16,20 Finally and most importantly, transplantation of blood-derived EPCs significantly augmented ischemia-induced neovascularization of the hindlimb 23,24 and promoted limb salvage in nude mice. 15 Thus, the finding that statin therapy augments the number of circulating EPCs in patients with CAD implies that vasculogenesis may contribute to statin-mediated repair after ischemic injury, which was very recently demonstrated for the rabbit model of hindlimb ischemia.…”

Section: Discussionmentioning

confidence: 93%

Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease

Vasa¹,

Fichtlscherer²

2001

ACC Current Journal Review

332

426

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 93%

Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease

Vasa¹,

Fichtlscherer²

2001

ACC Current Journal Review

332

426

View full text Add to dashboard Cite

“…4 Moreover, tissue implantation of CD34 ϩ cells isolated by cell apheresis from rhG-CSF-mobilized peripheral blood MNCs augmented ischemia-induced neovascularization. 21,23 Thus, G-CSF administration have been considered as an alternative method for therapeutic angiogenesis. However, Kang et al 10 recently demonstrated a high rate of in-stent restenosis after administration of rhG-CSF (10 g/kg per day) for 4 days in patients with severe coronary artery disease presumably by increased peripheral leukocytes and platelets, leaving a significant caution for the use of rhG-CSF for patients with coronary artery diseases.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic Angiogenesis With Intramuscular Injection of Low-Dose Recombinant Granulocyte-Colony Stimulating Factor

Lee

Aoki

Kondo

et al. 2005

ATVB

View full text Add to dashboard Cite

Objective-In vivo administration of granulocyte colony-stimulating factor (G-CSF) has been shown to facilitate regeneration of cardiovascular tissues. However, G-CSF causes marked leukocytosis that potentially induces adverse cardiovascular events. Earlier studies showed that G-CSF had direct stimulatory actions on mature endothelial cells, resulting in promotion of angiogenesis. We thus examined whether low doses of recombinant human G-CSF (rhG-CSF) locally injected into ischemic tissues would stimulate angiogenesis without inducing severe leukocytosis. Methods and Results-Reverse-transcription polymerase chain reaction (PCR) revealed expression of G-CSF receptor in human umbilical vein endothelial cells (HUVECs). rhG-CSF (100 ng/mL) enhanced migration and tube formation but not proliferation of HUVECs in vitro. We then examined the effects of rhG-CSF on angiogenesis in a rat model of hindlimb ischemia. Nude rats received in their ischemic skeletal muscles either rhG-CSF (2, 10, 20 g/kg per day) or saline (control) for 6 days. Laser Doppler blood flowmetry (LDBF) revealed an augmented ischemic/normal limb LDBF ratio and an increased capillary density in the rhG-CSF-treated groups compared with the control at days 14, 21, and 28 (PϽ0.05). These doses of rhG-CSF induced only mild leukocytosis (Ϸ1.4-fold increases versus baseline). Conclusions-rhG-CSF

show abstract

“…In vitro studies of EPCs isolated from diabetic patients have shown impairment in their proliferation, adhesion and incorporation into vascular structures, suggesting that EPC alterations may contribute to vascular dysfunction during diabetes (Tepper et al, 2002). Studies in a mouse model of diabetes showed impairment of vasculogenesis in response to hind limb ischemia (Schatteman et al, 2000). Studies in a model of ischemic retinopathy have shown that bone marrow-derived hematopoietic stem cells participate in retinal neovascularization (Grant et al, 2002).…”

Section: Vegf and Retinalmentioning

confidence: 99%

Vascular endothelial growth factor in eye disease

Penn

Madan

Caldwell

et al. 2008

Progress in Retinal and Eye Research

636

527

View full text Add to dashboard Cite

Collectively, angiogenic ocular conditions represent the leading cause of irreversible vision loss in developed countries. In the U.S., for example, retinopathy of prematurity, diabetic retinopathy and age-related macular degeneration are the principal causes of blindness in the infant, working age and elderly populations, respectively. Evidence suggests that vascular endothelial growth factor (VEGF), a 40 kDa dimeric glycoprotein, promotes angiogenesis in each of these conditions, making it a highly significant therapeutic target. However, VEGF is pleiotropic, affecting a broad spectrum of endothelial, neuronal and glial behaviors, and confounding the validity of anti-VEGF strategies, particularly under chronic disease conditions. In fact, among other functions VEGF can influence cell proliferation, cell migration, proteolysis, cell survival and vessel permeability in a wide variety of biological contexts. This article will describe the roles played by VEGF in the pathogenesis of retinopathy of prematurity, diabetic retinopathy and age-related macular degeneration. The potential disadvantages of inhibiting VEGF will be discussed, as will the rationales for targeting other VEGF-related modulators of angiogenesis.

show abstract

Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice

Cited by 454 publications

References 26 publications

Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease

Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease

Therapeutic Angiogenesis With Intramuscular Injection of Low-Dose Recombinant Granulocyte-Colony Stimulating Factor

Vascular endothelial growth factor in eye disease

Contact Info

Product

Resources

About